1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Acute Myeloid Leukemia (AML) Therapeutics Market
2.2. Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Drugs, 2023 (US$ Million)
2.3. Global Acute Myeloid Leukemia (AML) Therapeutics Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Acute Myeloid Leukemia (AML) Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Acute Myeloid Leukemia (AML) Therapeutics Market Vendors
3.2. Strategies Adopted by Acute Myeloid Leukemia (AML) Therapeutics Market Vendors
3.3. Key Industry Strategies
4. Acute Myeloid Leukemia (AML) Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Acute Myeloid Leukemia (AML) Therapeutics Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Cell Culture Vaccines
5.3.1.1. Cytarabine
5.3.1.2. Anthracyclines
5.3.1.3. Etoposide
5.3.1.4. Others
5.3.2. Pipeline Drugs


6. North America Acute Myeloid Leukemia (AML) Therapeutics Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
6.3.Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)

7. UK and European Union Acute Myeloid Leukemia (AML) Therapeutics Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
7.3.Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)

8. Asia Pacific Acute Myeloid Leukemia (AML) Therapeutics Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
8.3.Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)

9. Latin America Acute Myeloid Leukemia (AML) Therapeutics Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
9.3.Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)

10. Middle East and Africa Acute Myeloid Leukemia (AML) Therapeutics Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
10.3.Acute Myeloid Leukemia (AML) Therapeutics Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Acute Myeloid Leukemia (AML) Therapeutics Market: By Drugs, 2022-2032, USD (Million)

11. Company Profile
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Astex Pharmaceuticals (A subsidiary of Otsuka Pharmaceutical)
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Boehringer Ingelheim GmbH
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Bristol Myers Squibb
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Celegene Corporation
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Cephalon Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Eisai Co. Ltd.
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Eli Lilly and Company
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Genzyme Corporation (A subsidiary of Sanofi S.A.)
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Jazz Pharmaceuticals, Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Novartis AG
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Pfizer Inc.
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives